Dr Ruff is the director of general cardiology at Bringham and Women's Hospital, and also an associate professor at Harvard Medical School.
Dr Ruff Explores Mitigating Surgical Bleeding in AFib With Abelacimab
Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.
Abelacimab, a “Game Changer” for High-Risk Patients With AFib: Dr Ruff and Dr Bloomfield Elaborate on Latest Data From AZALEA-TIMI 71 Trial
Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients with atrial fibrillation (AFib).